Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-12

Clinical Trial Update: A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy of Fenebrutinib in Relapsing Multiple Sclerosis. Results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fenebrutinib (Fenebrutinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Relapsing Multiple Sclerosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-12